Table 7 Net clinical benefit of all patients, male patients and female patients with atrial fibrillation taking oral anticoagulants based on CHA₂DS₂-VASc score

Any OACs vs. No OACs

 CHA₂DS₂-VASc of 0–1

0.04 (0.04 to 0.05)

0.30 (0.19 to 0.41)

-1.55 (-3.16 to 0.07)

 CHA₂DS₂-VASc of 2

-1.78 (-2.07 to -1.49)

-2.31 (-2.84 to -1.78)

-0.49 (-0.49 to -0.49)

 CHA₂DS₂-VASc of ≥ 3

0.52 (0.33 to 0.73)

-2.06 (-2.36 to -1.75)

2.75 (2.09 to 3.43)

Warfarin vs. No OACs

 CHA₂DS₂-VASc of 0–1

-0.17 (-0.28 to -0.05)

0.14 (0.11 to 0.16)

-2.23 (-4.80 to 0.34)

 CHA₂DS₂-VASc of 2

-1.97 (-2.29 to -1.65)

-2.60 (-3.15 to -2.05)

-0.36 (-0.50 to -0.23)

 CHA₂DS₂-VASc of ≥ 3

0.38 (0.19 to 0.58)

-2.17 (-2.48 to -1.86)

2.61 (1.94 to 3.27)

DOACs vs. No OACs

 CHA₂DS₂-VASc of 0–1

1.18 (0.70 to 1.66)

1.23 (0.73 to 1.73)

0.91 (-0.88 to 2.71)

 CHA₂DS₂-VASc of 2

0.31 (-1.03 to 1.64)

1.41 (1.03 to 1.79)

-1.53 (-6.08 to 3.01)

 CHA₂DS₂-VASc of ≥ 3

2.19 (1.82 to 2.57)

-0.54 (-3.09 to 2.02)

4.38 (3.53 to 5.23)

Warfarin (TTR ≥ 65%) vs. No OACs

 CHA₂DS₂-VASc of 0–1

-0.33 (-1.31 to 0.64)

-0.54 (-1.73 to 0.65)

0.91 (-0.88 to 2.71)

 CHA₂DS₂-VASc of 2

-0.63 (-1.12 to -0.13)

-2.25 (-3.05 to -1.44)

0.46 (1.40 to -0.49)

 CHA₂DS₂-VASc of ≥ 3

2.63 (2.52 to 2.73)

0.43 (-0.16 to 1.01)

5.52 (4.83 to 6.22)

DOACs versus Warfarin

 CHA₂DS₂-VASc of 0–1

1.35 (0.80 to 1.90)

1.10 (0.67 to 1.53)

3.15 (-1.21 to 7.51)

 CHA₂DS₂-VASc of 2

2.28 (0.96 to 3.60)

4.01 (3.61 to 4.40)

-1.17 (-5.81 to 3.48)

 CHA₂DS₂-VASc of ≥ 3

1.81 (1.10 to 2.53)

1.63 (-1.52 to 4.79)

1.77 (1.29 to 2.26)

DOACs versus Warfarin (TTR ≥ 65%)

 CHA₂DS₂-VASc of 0–1

1.51 (-0.20 to 3.23)

1.77 (-0.23 to 3.77)

0.00 (0.00 to 0.00)

 CHA₂DS₂-VASc of 2

0.93 (-0.12 to 1.98)

2.43 (1.87 to 2.99)

-1.99 (-5.88 to 1.91)

 CHA₂DS₂-VASc of ≥ 3

-0.43 (-1.19 to 0.33)

-0.97 (-4.32 to 2.39)

-0.16 (-0.67 to 0.36)